Explore compound GLP3-R$280.00
Skip to content
RESEARCH, REFINED.
The details
Considered compounds. Documented standards.Explore our standard
RESEARCH, REFINED.Metabolic research
GLP3-R
30 mg / $200.00
GLP3-R is the house designation for a synthetic, acylated triple-agonist peptide of the incretin family — a single engineered sequence that engages three receptor pathways at once: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor.
1
Availability and final pricing are checked at checkout.
1 laboratory report availableFor laboratory research use only. Not for human consumption.
A closer look
The details
behind the compound.
Overview
GLP3-R is the house designation for a synthetic, acylated triple-agonist peptide of the incretin family — a single engineered sequence that engages three receptor pathways at once: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor.
Research interest centers on how one molecule balances activity across three related class-B receptors, and on how that balance reads against single- and dual-agonist reference peptides. It is offered strictly as a laboratory reference compound.
Laboratory documentation
Check the product format and report identifiers before comparing results. Available reports do not establish the lot currently held in stock.
Vanguard LaboratoryAnalysis report · Lot R26C978View reportResearch references
Finan B, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015.
Capozzi ME, et al. Targeting the incretin/glucagon system with triagonists to treat diabetes. Endocr Rev. 2018.
Storage & handling
Store the lyophilized peptide at −20°C, desiccated and protected from light; −80°C for the longest terms. Reconstituted solution is aliquoted, held at 2–8°C, and used within a short window; avoid repeated freeze-thaw.
